0.5357

4.36% 0.0224

Optinose Inc (OPTN)

Overview News Price History Financials Why OPTN Down? Discussions Forecast

Optinose Inc stock is traded at $0.5357, with a volume of 719.58K. It is up +4.36% in the last 24 hours and down -30.55% over the past month. OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Previous Close:

$0.5133

Open:

$0.53

24h Volume:

719.58K

Relative Volume:

1.10

Market Cap:

$83.71M

Revenue:

$70.99M

Net Income/Loss:

$-35.48M

P/E Ratio:

-1.0714

EPS:

-0.5

Net Cash Flow:

$-20.86M

1W Performance:

+45.97%

1M Performance:

-30.55%

6M Performance:

-51.74%

1Y Performance:

-55.36%

1-Day Range:

$0.5138

$0.5766

1-Week Range:

$0.36

$0.5766

52-Week Range:

$0.321

$2.10

Optinose Inc Stock (OPTN) Company Profile

Name

Optinose Inc

Sector

Healthcare (1200)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

267-364-3500

Address

777 TOWNSHIP LINE ROAD, YARDLEY, PA

Employee

132

Twitter

@optinose

Next Earnings Date

2024-11-07

Latest SEC Filings

OPTN's Discussions on Twitter

Compare OPTN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OPTN Optinose Inc	0.5357	83.71M	70.99M	-35.48M	-20.86M	-0.50
ZTS Zoetis Inc	176.74	80.59B	9.15B	2.43B	2.31B	4.92
HLN Haleon Plc Adr	9.72	44.17B	14.26B	1.55B	0	0.3327
TAK Takeda Pharmaceutical Co Adr	13.57	42.61B	30.27B	1.93B	3.45B	0.444
TEVA Teva Pharmaceutical Industries Ltd Adr	16.57	18.77B	16.77B	-959.00M	1.37B	-2.00
VTRS Viatris Inc	13.22	15.73B	15.05B	-883.30M	1.89B	1.53

Optinose Inc Stock (OPTN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-11-24	Initiated	H.C. Wainwright	Buy
Aug-21-23	Initiated	Lake Street	Buy
Oct-21-22	Resumed	Jefferies	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Dec-18-19	Initiated	Cowen	Outperform
Aug-08-18	Initiated	Cantor Fitzgerald	Overweight

View All

Optinose Inc Stock (OPTN) Latest News

Nov 26, 2024

OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 31% - Simply Wall St

Nov 26, 2024

91,084 Shares in OptiNose, Inc. (NASDAQ:OPTN) Acquired by GSA Capital Partners LLP - Defense World

Nov 26, 2024

Nov 20, 2024

Stonepine Capital Management, LLC Increases Stake in OptiNose Inc - GuruFocus.com

Nov 20, 2024

OptiNose (OPTN) Reports Break-Even Earnings for Q3 - MSN

Nov 20, 2024

OptiNose (STU:0OP) Owner Earnings per Share (TTM) : -0.31 (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Optinose to Announce Q3 2024 Financial Results with Investor Call - MSN

Nov 20, 2024

OptiNose (STU:0OP) 5-Year EBITDA Growth Rate : 41.10% (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Nov 19, 2024

OptiNose stock plunges to 52-week low at $0.37 amid market challenges - Investing.com

Nov 19, 2024

Nov 16, 2024

FY2024 EPS Estimates for OptiNose Increased by HC Wainwright - Defense World

Nov 16, 2024

Nov 15, 2024

Earnings Release: Here's Why Analysts Cut Their OptiNose, Inc. (NASDAQ:OPTN) Price Target To US$3.50 - Simply Wall St

Nov 15, 2024

OptiNose, Inc. (NASDAQ:OPTN) Just Reported, And Analysts Assigned A US$3.50 Price Target - Yahoo Finance

Nov 15, 2024

OptiNose Third Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.083 loss in 3Q 2023) - Yahoo Finance

Nov 14, 2024

Optinose stock target down as analyst cites challenges in Xhance sales guidance - Investing.com UK

Nov 14, 2024

Nov 13, 2024

Optinose Reports Q3 2024 Financial Results, Highlights XHANCE Performance - MyChesCo

Nov 13, 2024

OptiNose (NASDAQ:OPTN) Given Buy Rating at HC Wainwright - MarketBeat

Nov 13, 2024

OptiNose, Inc. (NASDAQ:OPTN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024